Travere Therapeutic TVTX 深 滬
等待開盤 11-05 09:30:00 美东时间
52.42
+3.010
+6.09%
華盛通- 最 高53.30
- 今 開50.27
- 成交量 366.87万股
- 最 低 49.16
- 昨 收 49.41
- 總市值 50.32亿
- 52周最高 68.73
- 市盈率 靜 --
- 換手率 3.82%
- 52周最低 22.59
- 委 比 -22.77%
- 總股本 9599.22万
- 歷史最高 68.73
- 量 比 1.13
- 振 幅 8.38%
- 歷史最低 0.90
- 每 手 1
- 風險率 12.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $78
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and lowers the price target from $89 to $78.
11-04 23:19
财报速睇 | Travere Therapeutic 2026财年Q3营收2.25亿美元，同比增长36.2%；归母净利润亏损0.52亿美元，由盈转亏
华盛资讯11月3日讯，Travere Therapeutic公布2026财年Q3业绩，公司Q3营收2.25亿美元，同比增长36.2%，归母净利润亏损0.52亿美元，由盈转亏。
11-03 06:01
财报速睇 | Travere Therapeutic 2026财年Q3营收2.25亿美元，同比增长36.2%；归母净利润亏损0.52亿美元，由盈转亏
华盛资讯11月3日讯，Travere Therapeutic公布2026财年Q3业绩，公司Q3营收2.25亿美元，同比增长36.2%，归母净利润亏损0.52亿美元，由盈转亏。
11-03 05:18
Travere Therapeutics Q3 Adj. EPS $(0.31) Misses $(0.06) Estimate, Sales $224.563M Beat $195.292M Estimate
Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.06) by 416.67 percent. This is a 152.54 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $224....
11-03 05:01
Travere Presents Phase 3 FILSPARI Biomarker Data in IgA Nephropathy
Travere Therapeutics presented Phase 3 PROTECT biomarker findings suggesting FILSPARI may modify underlying disease pathophysiology in adults with IgA nephropathy.
10-23 23:31
AstraZeneca PLC Stock (AZN) Moved Up by 3.04% on Oct 22: A Full Analysis
• FDA granted accelerated approval for Ultomiris to treat primary IgA nephropathy. • AstraZeneca reports annual revenue of $58.74B and net profit of $10.22B. • Analysts issued Buy ratings with an average price target of $210.32.
10-22 18:15
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target
Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $76 price target.
09-22 20:38
Travere Therapeutics appoints new CEO Bradley Campbell
Travere Therapeutics ( ($TVTX) ) has issued an announcement. On September 21, 2...
09-22 04:55
